An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Janssen (J&J Innovative Medicine)

Status and phase: Completed; Phase 3

Conditions: Chronic Hepatitis C

Treatments: Drug: Telaprevir; Drug: Ribavirin; Drug: Pegylated-Interferon-alfa-2a

Study type: Interventional

Funder types: Industry

Identifiers

NCT01513941

VX-950HPC3008 (Other Identifier)

2011-004928-35 (EudraCT Number)

CR100778

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both chronic hepatitis C virus (HCV-1) and human immunodeficiency virus (HIV-1).

Full description

This is an open-label (both participant and investigator know the name of the medication given at a certain moment), single-arm, multicenter study in HCV treatment-naive and treatment-experienced patients infected with both chronic HCV-1 and HIV-1 to determine the efficacy and safety of telaprevir given with Peg-IFN-alfa-2a and RBV. The study will consist of 3 phases: a screening phase, an open-label treatment phase up to 48 weeks, and a follow-up period of 24 weeks. All patients will receive 12 weeks of treatment with telaprevir given with Peg-IFN-alfa-2a and RBV. At week 12 telaprevir dosing will end and patients will continue on Peg-IFN-alfa-2a and RBV. The total treatment duration in this study will be 24 or 48 weeks depending on the patient's prior HCV treatment status, liver disease status, and individual on-treatment virologic response in this study (equal response guided therapy). The maximum total duration of participation in the study for an individual participant will be approximately 76 weeks (screening included). Approximately 150 patients infected with both chronic HCV-1 and HIV-1 are planned to be enrolled.

Enrollment: 163 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic (detectable HCV Ribonucleic acid (RNA) more than 6 months prior screening or histological diagnosis based on liver biopsy or fibroscan) HCV infection genotype 1 with HCV RNA level greater than 1,000 IU/mL
• Confirmed diagnosis of HIV-1 infection greater than 6 months before the screening visit
• CD4 count greater than 300 cells/mm3 at screening and no value less than 200 cells/mm3 within 6 months of screening visit
• HIV-1 RNA undetectable by an ultrasensitive assay at least once within 90 days of the screening visit
• No HIV RNA values greater than 200 copies/mL within 6 months of the screening visit
• Currently taking one of the permitted anti-HIV regimens for greater than or equal to12 weeks

Exclusion criteria

• Anticipated need to switch anti-HIV regimen from screening through the Telaprevir treatment period
• Infection or co-infection with HCV other than genotype 1
• Contraindication to the administration of Peg-IFN-alfa or RBV
• Hepatitis B virus (HBV) co-infection
• Acute or active condition of HIV-associated opportunistic infection within 6 months of screening

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

163 participants in 1 patient group

Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)

Experimental group

Description:

All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.

Treatment:

Drug: Telaprevir

Drug: Pegylated-Interferon-alfa-2a

Drug: Ribavirin